That is very important, because the method a protein in the human body folds identifies if a pharmaceutical will be able to bind to that protein and work. Simply put, we need to understand how these proteins fold if we desire a drug to work. Historically, this has been a trial-and-error procedure (korean actress). Now, Alpha, Fold can predict protein folding with 92. 4% precision. That's going to make it a lot easier to produce drugs that do what they're developed to do. This was a breakthrough practically nobody discovered. But it's going to have extensive ramifications for curing disease. I predict that Alpha, Fold will be 98% precise by the end of 2021.
And, obviously, there will be plenty of investment chances in this area, too. Shifting topics It's going to be a great year for bitcoin. I'm bullish on it in 2021 (exponential growth). That stated, I still believe bitcoin will continue to be volatile. We're close to all-time highs. I wouldn't be amazed if it pulled back perhaps significantly prior to going higher - jeff brown stock predictions. I have actually been covering bitcoin for a long period of time now. Among the very first research study reports I ever released was on bitcoin. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
However at the time of that preliminary suggestion, I titled my report "What's the Big Deal With Bitcoin?" That shows you where the conversation was at the time. We were mostly informing readers. But that's not the big question anymore. Now we're seeing institutional cash lastly take an interest in bitcoin. Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some small, niche enterprise. Mass, Mutual is a trusted 170-year-old organization. So consider that. In five years, we went from educating readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake.
Which's a huge reason I'm bullish on it this year. jeff brown genetic sequencing stock. Regards, Jeff Brown, Editor, The Bleeding Edge I have a benefit forecast 2020 was a record year for IPOs. 552 U.S. companies went public the most in more than 20 years. These companies raised a total of $172 billion. That's an all-time high beating the previous annual record by 43%. I anticipate 2021 will be another record year in IPOs. There are so lots of great personal business on the edge of striking the general public markets And I have actually been dealing with a brand-new way for you to invest even before these companies go public.
This opportunity has been building over the last few years. I can't wait to tell you everything about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Event to learn all the details. Go right here to book your spot for complimentary.
Emma Walsh here, managing editor of the Journal. Routine Journal readers know that tech isn't our normal beat (jeff brown genome sequencing stock). And when it pertains to tech investing, we leave it to the specialists. The good news is, we have a number of such professionals in our Rolodex. Our associate Jeff Brown will recognize to our long time readers. He is among the most accomplished tech investing specialists we understand (jeff brown biotech stock). In truth, he had a number of triple-digit returns in his Brownstone Research portfolios last year. Here's what Jeff believes the tech sector will bring us in 2021 Each year, I like to have a look at the big image and forecast what's simply around the corner.
That includes things like 5G networks, biotech, expert system, and much more. These patterns are experiencing exponential growth and developing extraordinary opportunities for financiers. I want to ensure all our readers are prepared for what's next. And with that in mind, let me draw the image of what I see coming in the next 12 months Our new 5G (fifth-generation) wireless networks are a topic I've been covering for years now. jeff brown latest prediction. But regardless of what many readers may believe, this is a trend that's just starting. Although the COVID-19 pandemic interrupted supply chains in 2015, an outstanding 250 million 5G-enabled gadgets were still sold.
And all of this eventually resulted in Apple postponing the release of the 5G-enabled i, Phone 12 by 2 months (jeff brown biotech stocks). Losing two months of manufacturing and sales actually affects the number of 5G devices are sold in the calendar year. When you consider all of that, selling 250 million systems is amazing. More significantly, the hold-ups triggered by the pandemic created a load of pent-up demand. And that demand is now going to be pressed into 2021. In fact, I forecast that more than 500 million 5G devices will be shipped in 2021 - jeff brown biotech stocks. And that's not my only 5G forecast When I have actually discussed 5G in the past, I've described its 3 different phases.
In Phase 2, 5G gadgets go on sale. 5G phones and other items start to reach consumers. And in Stage Three, 5G services start to be offered (biotech stock). That's when we start to see applications operating on 5G networks. Think about things like massive multiplayer video games over a smart phone. That's not possible with 4G. It will be with 5G. And my second 5G prediction for 2021 is that we will start Stage Three by this summer season. This starts something of a virtuous cycle: Many people do not really appreciate the technology. But they will care if there are exciting applications that can just be accessed with a 5G phone.
That causes more 5G apps being developed. In reality, 5G is going to open up a suite of unbelievable applications: self-driving automobiles, the Web of Things, robotic surgery, and more. All of these technologies need 5G. The investment chances moving forward will be massive. Stepping away from 5G, the next essential technology I anticipate in 2021 is CRISPR genetic editing. CRISPR represents "clustered regularly interspaced short palindromic repeat." It's a mouthful. But it is among the most exciting developments in biotechnology. At a high level, CRISPR is a technology that can edit our genetic makeup as if it were software.
The program can crash or not function properly. CRISPR uses a comparable concept but with our genetic code. "Typos" in our genome can cause disease. CRISPR can correct these "typos." For many years, CRISPR was primarily a specific niche innovation that wasn't well understood. And throughout that time, there were really only 3 business operating in this area. However things are altering. CRISPR is no longer simply theoretical. We're seeing real outcomes. We're treating diseases and seeing that this technology simply works. And as a result, a "2nd crop" of early-stage CRISPR business is going public and providing incredible returns. This whole industry is effectively a greenfield opportunity.
There's room for lots of companies to exist in this area. future report review. And there will be more. That's my forecast for CRISPR in 2021. I anticipate that 2 or three more genetic editing business will hold their IPOs. Sticking with biotechnology, we are seeing fantastic things happening at the convergence of biotech and synthetic intelligence (AI). Google's AI subsidiary, Deep, Mind, simply revealed at the end of 2020 that its most current Alpha, Fold software application can accurately forecast the folding of a protein based entirely on its amino acid sequence with 92. 4% precision. That is essential since the method a protein in the body folds identifies if a pharmaceutical will be able to bind to that protein and be effective.
Historically, this has actually been an experimental procedure. And now, Alpha, Fold can forecast protein folding with 92. 4% precision. That's going to make it much simpler to develop drugs that do what they're designed to do. And here's my next prediction. I predict that Alpha, Fold will be 98% accurate by the end of 2021. And we will see not simply one but a number of drug therapies produced using this innovation. This was one of those developments that almost nobody noticed. However it's going to have profound implications for treating disease. And, obviously, there will be a lot of investment opportunities in this area, too.
It's going to be a good year for bitcoin. I'm bullish on it in 2021. That said, I still believe bitcoin will continue to be volatile. We're close to all-time highs. I would not be amazed if it drew back maybe significantly before going greater. I've been covering bitcoin for a long time now. One of the first research study reports I ever published was on bitcoin - jeff brown genome sequencing stock. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ return on financial investment for any person who followed my recommendation. However at the time of that preliminary recommendation, I entitled my report, "What's the Big Deal With Bitcoin?" That reveals you where the discussion was at the time.
However no one is asking that concern anymore. Now, we're seeing institutional money finally taking an interest in bitcoin. The huge news was that Massachusetts Mutual Life Insurance took a $100 million stake in bitcoin in December. This is not some small, niche enterprise. jeff brown biotech pick. Mass, Mutual is a 150-year-old organization. So think about that. In 5 years, we went from informing readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. And that's a huge reason I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have one more benefit forecast In 2021, we're going to have another record year in IPOs. One website reports that Jeff Brown deserves about $27. 5 million and claims the info depends on date as of February 2021, however we could not separately confirm this claim. Offered Jeff Brown's past, he likely has a considerable net worth, however we can't hammer down an exact figure at this minute. Brown is best known for his sage-like ability to select winning innovation stocks. He invested more than 25 years investigating innovation business like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's substantial experience gives him an excellent perspective on the market. He's constantly on the hunt for new chances, and he shares a number of his best picks in the Future Report.
That's full marks, but it's not ridiculously reasoned. Brown has an excellent track record as a stock-picker, and he successfully anticipated some of the most significant financial occasions of the past 20 years. Although he does not appear to launch his picks to the general public, the service's success is a direct indicator of Brown's stock-picking expertise. Nobody on Wall Street gets it right each time, however Jeff Brown's precise forecasts have made him legions of devoted fans. That says a lot about his capability. The Near Future Report is released by Brownstone Research, a popular monetary research study publisher. Brownstone Research study uses numerous research study services with a wide variety of expertises - jeff brown biotech genome sequencing.
The company is likewise associated with Bonner & Partners, another well-respected research publisher - jeff brown 2021 predictions. On its site, Brownstone says its mission is to offer retail financiers with professional-grade research: "For too long, the finest financial investment research study has actually not been readily available to individual financiers. It has actually been typically booked for investment banks, hedge funds, personal equity, and high-net-worth customers. jeff brown 2021 stock predictions. The mission of Brownstone Research is to make that type of exclusive research study offered to any investors aiming to gain an edge in the marketplaces. The objective is easy to deliver unique and rewarding financial investment research study found nowhere else." -Brownstone Research website excerpt from the Jeff Brown is the creator of Brownstone Research, and he also functions as the firm's Chief Investment Analyst.
With Brown assisting the ship, Brownstone Research study is a powerhouse publisher with lots to use its customers. After years of consistent success at the helm of top-tier companies like Tesla and Space, X, Elon Musk is a home name throughout the majority of America. If you understand even a bit about the marketplace, you understand that he has a credibility as a King Midas of sorts. biotech stock. Whatever he touches turns to gold! Jeff is aware of Elon Musk's executive expertise, so he always has an eye out for the Silicon Valley rock star's next relocation. This time, Jeff has an early lead on Elon's next huge task.
In truth, Brown thinks S.A.V. democratic republic. might be "the biggest trend of the 2020s, and he's not alone. Have a look at these quotes from other popular S.A.V. bulls: Elon's next big act will be marrying two innovative technologies: synthetic intelligence and electric automobiles. Musk hopes the mix will help him develop the first fully-autonomous, self-driving automobiles ever. It's nothing except the vehicle industry's Holy Grail. As you know, electrical vehicles and self-driving cars and truck stocks have actually been huge this year, however the Wall Street machine has actually been huge on hype without much concrete result. Regardless of a drastic boost in competition over the previous few years, Brown still believes Musk has the very best possibility of putting it all together.
tech might be the magic string that ties everything together. S.A.V. represents Shared Autonomous Car, and it could be the future of transportation. Basically, this technology would permit you to lease out your cars and truck as a self-governing, self-driving taxi when you're not using it. You merely get out of the vehicle and press a button on an app that informs the cars and truck to "sign up with the fleet." Next thing you understand, you're relaxing on your sofa while your car shuttles ride-sharers around town. Best of all, you get to keep a significant piece of the revenues. It sounds crazy, however it could be closed than you think.